Patient characteristics, visual acuity and treatment
| Case | Age (years) | Sex | Eye | BCVA at diagnosis, decimal (log MAR) | BCVA at last visit, decimal (logMAR) | Antiviral treatment | Oral prednisone days before (−) or after (+) antivirals | Last follow-up (months) |
| 1 | 63 | F | R | 0.1 (1.0) | 0.01 (2.0) | 10 mg/kg × 3 intravenous acyclovir | −48 | 23 |
| 2 | 56 | M | R | HM (2.9) | NLP (3.4) | 5 mg/kg × 3 intravenous acyclovir* | +3 | 10 |
| 3 | 37 | M | R | 0.1 (1.0) | 0.4 (0.4) | 10 mg/kg × 3 intravenous acyclovir | +3 | 11 |
| 4 | 22 | F | L | 0.05 (1.3) | HM (2.3) | 10 mg/kg × 3 intravenous acyclovir | +3 | 57 |
| 5 | 40 | M | R | 0.4 (0.4) | LP (3.1) | 10 mg/kg × 3 intravenous acyclovir | +3 | 28 |
| 6 | 71 | M | L (Bi) | 0.2 (0.7) | 0.04 (2.4) | Oral valacyclovir 500 mg × 2 | +11 | 6 |
| 7 | 60 | F | L | 0.3 (0.5) | 0.5 (0.3) | 10 mg/kg × 3 intravenous acyclovir | +3 | 58 |
| 8 | 63 | F | R | 0.3 (0.5) | 0.07 (1.16) | 10 mg/kg × 3 intravenous acyclovir | +3 | 21 |
| 9 | 43 | M | L | 0.5 (0.3) | 0.8 (0.1) | 10 mg/kg × 3 intravenous acyclovir | −2 | 19 |
| 10 | 55 | F | L | 0.01 (2.0) | 0.01 (2.0) | 10 mg/kg × 3 intravenous acyclovir | +3 | 13 |
| 11 | 58 | F | R | 0.2 (0.7) | 0.16 (0.8) | 10 mg/kg × 3 intravenous acyclovir† | +7 | 13 |
| 12 | 68 | F | R | CF (2.6) | 0.1 (1.0) | 10 mg/kg × 3 intravenous acyclovir | +3 | 5 |
| 13 | 45 | F | R (Bi) | 0.05 (1.3) | 0.01 (2.0) | 10 mg/kg × 3 intravenous acyclovir | DM | 4 |
*Reduced dose due to kidney failure.
†Low dose oral acyclovir four days prior to diagnosis.
BCVA, best corrected visual acuity;CF, counting fingers;DM, data missing; F, female;HM, hand movements;L, left;LP, light perception;M, male;NLP, no light perception;R, right.